688321 微芯生物
2024/09 - 九个月2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)-3.0475.5091.1921.5082.112
总资产报酬率 ROA (%)-1.5622.9130.7301.2131.817
投入资产回报率 ROIC (%)-1.7143.3360.8561.3631.999

边际利润分析
销售毛利率 (%)87.57689.12294.34194.98794.999
营业利润率 (%)-9.33218.5353.0145.17113.724
息税前利润/营业总收入 (%)-6.43421.5883.4184.0088.595
净利润/营业总收入 (%)-10.6189.3922.4185.10111.521

收益指标分析
经营活动净收益/利润总额(%)86.423-201.58222.558-62.58324.044
价值变动净收益/利润总额(%)33.361290.69515.83229.6618.741
营业外收支净额/利润总额(%)-0.016-0.055-5.388-19.676-2.248

偿债能力分析
流动比率 (X)2.8882.8922.1912.1745.236
速动比率 (X)2.7582.7712.1382.1225.151
资产负债率 (%)50.77246.62045.58725.16813.465
带息债务/全部投入资本 (%)39.46234.16729.8494.267-0.130
股东权益/带息债务 (%)136.256172.198209.8781,993.300-73,855.132
股东权益/负债合计 (%)96.960114.500114.800297.323642.670
利息保障倍数 (X)-2.2227.0496.129-12.816-1.780

营运能力分析
应收账款周转天数 (天)95.998120.07389.98363.93653.152
存货周转天数 (天)218.050238.879263.140231.585312.112